Min Fang
Directeur/Membre du Conseil chez InSilico Medicine, Inc.
Profil
Min Fang is currently a Director at InSilico Medicine, Inc. and a Non-Executive Director at InSilico Medicine Cayman TopCo. Previously, Mr. Fang served as a Non-Executive Director at Hygeia Healthcare Holdings Co., Ltd.
Mr. Fang completed their undergraduate degree at Fudan University.
Postes actifs de Min Fang
| Sociétés | Poste | Début |
|---|---|---|
InSilico Medicine, Inc.
 InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Directeur/Membre du Conseil | - |
Insilico Medicine Cayman TopCo
 Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | 01/06/2021 |
Anciens postes connus de Min Fang
| Sociétés | Poste | Fin |
|---|---|---|
| HYGEIA HEALTHCARE HOLDINGS CO., LIMITED | Directeur/Membre du Conseil | 01/10/2021 |
Formation de Min Fang
| Fudan University | Undergraduate Degree |
| Stanford University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HYGEIA HEALTHCARE HOLDINGS CO., LIMITED | Health Technology |
| Entreprise privées | 2 |
|---|---|
InSilico Medicine, Inc.
InSilico Medicine, Inc. Packaged SoftwareTechnology Services Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014. | Technology Services |
Insilico Medicine Cayman TopCo
Insilico Medicine Cayman TopCo Miscellaneous Commercial ServicesCommercial Services InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong. | Commercial Services |
